The DOI matches its Crossref record; 153 of the 161 references it cites were found in a registry or an index; 18 of the 135 sources its claims cite were checked for support.
Aminolevulinic Acid (ALA) as a Prodrug in Photodynamic Therapy of Cancer
Open accessAbstract
Aminolevulinic acid (ALA) is an endogenous metabolite normally formed in the mitochondria from succinyl-CoA and glycine. Conjugation of eight ALA molecules yields protoporphyrin IX (PpIX) and finally leads to formation of heme. Conversion of PpIX to its downstream substrates requires the activity of a rate-limiting enzyme ferrochelatase. When ALA is administered externally the abundantly produced PpIX cannot be quickly converted to its final product - heme by ferrochelatase and therefore accumulates within cells. Since PpIX is a potent photosensitizer this metabolic pathway can be exploited in photodynamic therapy (PDT). This is an already approved therapeutic strategy making ALA one of the most successful prodrugs used in cancer treatment.
Overview
CoChat Summary
## TL;DR
This paper is a review of aminolevulinic acid (ALA) as a prodrug for photodynamic therapy (PDT) in cancer, explaining how exogenous ALA leads to protoporphyrin IX (PpIX) accumulation and selective tumor killing after light exposure. It argues that ALA-PDT is a highly promising, clinically approved strategy, but its effectiveness is limited by poor penetration, pain, light depth, and variable PpIX accumulation.
## Key findings
- Exogenous ALA bypasses normal heme-regulated control, causing PpIX to accumulate because ferrochelatase cannot convert it to heme quickly enough; light exposure after about 4–6 hours activates PpIX and generates cytotoxic singlet oxygen.
- Tumor selectivity is linked to heme-pathway differences: decreased ferrochelatase activity, limited iron availability, and increased activity of PpIX-producing enzymes such as ALAD, UROD, and PBGD contribute to higher PpIX in tumors than in normal cells.
- Reported clinical outcomes include 50%–100% complete responses for superficial basal cell carcinoma, 43% recurrence at 60 months, 100% response with no recurrence after 18 months in cutaneous T-cell lymphoma, and 68%–75% complete response after single MAL-PDT for actinic keratosis.
- The paper states that at least 77 ALA modifications and carriers have been reported to improve delivery, reflecting strong interest in overcoming ALA’s limited skin and tissue penetration.
## Methods
- Narrative review of the literature on ALA metabolism, pharmacokinetics, preclinical PDT studies, clinical indications, and ALA derivatives.
- Synthesizes prior experimental and clinical studies in multiple systems, including cell lines, mouse and rat models, and human clinical trials.
- Main analysis is qualitative: it compares reported mechanisms, delivery strategies, and treatment outcomes rather than presenting a new dataset or original statistical analysis.
## Limitations
- The paper states that ALA-PDT is limited by light hypersensitivity, inefficiency for large or metastatic tumors, pain during treatment, and limited tissue penetration.
- It also states that topical and even systemic ALA penetrate tissues only poorly, restricting efficacy; for topical use, PpIX fluorescence is seen only to a depth of 0.3 to 0.6 mm.
- Evident from the text: this is a review, so its conclusions depend on prior studies and are not based on a single controlled experiment or newly collected patient cohort.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
17 Valid · 3 Not valid · 72 Not checked · 20 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Enhanced activity of enzymes leading to production of PpIX, such as ALAD [43], UROD [43], or PBGD [38,43,44] has also been observed in tumor cells.”
§ Aminolevulinic Acid (ALA) as a Prodrug in Photodynamic Therapy of Cancer > 2. Metabolism of ALA > 2.4. Selectivity of PpIX Accumulation in Tumor Tissue in Response to ALA Administration
What the sources say
- Not checked — no full text of the sourcecites [43] Navone, 1990, Heme biosynthesis in human breast cancer--mimetic "in vitro" studies and some heme enzymic activity levels, Int. J. Biochem. source
- Partly supportedcites [38] Hinnen, 1998, Biochemical basis of 5-aminolaevulinic acid-induced protoporphyrin IX accumulation: A study in patients with (pre)malignant lesions of the oesophagus, Br. J. Cancer sourceExperimental — accuracy not yet measured
The Discussion (p. 681) reports increased PBG-D activity in malignant and premalignant oesophageal tissue compared with normal squamous epithelium, supporting the PBGD part of the citation. The paper reports measuring PBG-D and ferrochelatase, but the passages found do not report enhanced ALAD or UROD activity in tumor cells. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [44] Kondo, 1993, Heme-biosynthetic enzyme activities and porphyrin accumulation in normal liver and hepatoma cell lines of rat, Cell. Biol. Toxicol. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“PpIX has been found to preferentially accumulate in tumor as compared with normal cells.”
§ Aminolevulinic Acid (ALA) as a Prodrug in Photodynamic Therapy of Cancer > 2. Metabolism of ALA > 2.4. Selectivity of PpIX Accumulation in Tumor Tissue in Response to ALA Administration
What the sources say
- Supportedcites [38] Hinnen, 1998, Biochemical basis of 5-aminolaevulinic acid-induced protoporphyrin IX accumulation: A study in patients with (pre)malignant lesions of the oesophagus, Br. J. Cancer source
The Discussion (p. 682) says the study's results provide evidence for selective PPIX accumulation between normal and neoplastic tissue of the oesophagus. This supports the claim that preferential tumour accumulation has been found, without implying it occurs in every tumour type. (LLM, conf=0.90)
- Not checked — no full text of the sourcecites [39] Krieg, 2000, Cell-type specific protoporphyrin IX metabolism in human bladder cancer in vitro, Photochem. Photobiol. doi:10.1562/0031-8655(2000)072
- Not checked — no full text of the sourcecites [40] Hefti, 2011, Susceptibility to 5-aminolevulinic acid based photodynamic therapy in WHO I meningioma cells corresponds to ferrochelatase activity, Photochem. Photobiol. source
- Not checked — no full text of the sourcecites [41] Ohgari, 2005, Mechanisms involved in delta-aminolevulinic acid (ALA)-induced photosensitivity of tumor cells: Relation of ferrochelatase and uptake of ALA to the accumulation of protoporphyrin, Biochem. Pharmacol. source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In 1987 ALA was used for the first time in photodynamic therapy as a porphyrin precursor for selective elimination of erythroleukaemic cells [89].”
§ Aminolevulinic Acid (ALA) as a Prodrug in Photodynamic Therapy of Cancer > 6. Preclinical Studies with ALA
What the sources say
- Partly supportedcites [89] Malik, 1987, Destruction of erythroleukaemic cells by photoactivation of endogenous porphyrins, Br. J. Cancer sourceExperimental — accuracy not yet measured
The Summary (p. 589) reports that 5-ALA stimulated porphyrin synthesis in Friend erythroleukaemic cells and that light exposure selectively destroyed the cells. The paper does not establish that this was the first use of ALA in photodynamic therapy; that priority claim is unsupported by our copy. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Enhancement of PDT effects has been also observed after removal of iron with different iron-chelating substances such as desferrioxamine [51] or CP94 [52].”
§ Aminolevulinic Acid (ALA) as a Prodrug in Photodynamic Therapy of Cancer > 2. Metabolism of ALA > 2.5. Modifications of Heme Biosynthetic Pathway and Its Influence on ALA-PDT
What the sources say
- Supportedcites [51] Tan, 1997, Enhancement of photodynamic therapy in gastric cancer cells by removal of iron, Gut source
The Abstract (p. 1) of Tan et al. (1997) states 'PDT using ALA can be improved by removal of available iron with desferrioxamine', with 200 µmolar desferrioxamine trebling PPIX accumulation and low doses (0–30 µmolar) reducing cell viability after light exposure; the Discussion (QUANTITATION OF PORPHYRIN section) adds that adding iron abrogated the desferrioxamine effect, supporting iron removal as the mechanism. This covers the part of the citing sentence offered to this source (desferrioxamine); CP94 is carried on a separate citation [52] and is not mentioned anywhere in our copy. The source's demonstration is in an in vitro gastric cancer cell line (AGA) with ALA/PDT, and it notes a paradoxical protective effect at higher desferrioxamine doses ('J'-shaped curve, Conclusion), so the enhancement is dose-related rather than unconditional. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [52] Blake, 2010, The hydroxypyridinone iron chelator CP94 can enhance PpIX-induced PDT of cultured human glioma cells, Photochem. Photobiol. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Compared with cryotherapy for actinic keratosis MAL-PDT was found to have a better or similar effectiveness (complete response rate 68%–75% after single treatment) [129,130].”
§ Aminolevulinic Acid (ALA) as a Prodrug in Photodynamic Therapy of Cancer > 7. Clinical Indications for ALA and Its Esters
What the sources say
- Partly supportedcites [129] Tarstedt, 2005, A randomized multicenter study to compare two treatment regimens of topical methyl aminolevulinate (Metvix)-PDT in actinic keratosis of the face and scalp, Acta Derm. Venereol. sourceExperimental — accuracy not yet measured
Our copy of Tarstedt et al. (Abstract) shows this was a head-to-head comparison of two MAL-PDT schedules (single treatment vs two treatments 1 week apart) in 211 patients with thin-to-moderately thick actinic keratoses of the face and scalp; there is no cryotherapy arm and no cryotherapy comparison anywhere in the text we hold (searched: cryotherapy, liquid nitrogen, freezing, comparison with previous studies). The single-treatment complete response figures it does report — 93% (87–97%) for thin lesions and 70% (60–78%) for thicker lesions — only partly fall inside the 68%–75% range the citing sentence attributes, and the 'better or similar effectiveness compared with cryotherapy' claim is not supported by this source. (LLM, conf=0.70)
- Not checked — no full text of the sourcecites [130] Freeman, 2003, A comparison of photodynamic therapy using topical methyl aminolevulinate (Metvix) with single cycle cryotherapy in patients with actinic keratosis: A prospective, randomized study, J. Dermatolog Treat. source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
43 more claims
Create a free account to see all 112 claims and to verify the 10 references still open.
- It may state two separate claims as one. 45
- Probably not a substantial claim. 29
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“ALA administered topically or systemically is non-selectively taken up into cells and metabolized into photosensitive PpIX by the resident enzyme machinery [8].”
From Photodynamic Therapy for Non-Melanoma Skin Cancers (2016) · cites this paper as [8]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Aminolevulinic Acid (ALA) as a Prodrug in Photodynamic Therapy of Cancer > 5. Comparison of ALA with Porphyrin-based Photosensitizers
“ALA is the only photosensitizer registered for topical use, particularly useful for the local treatment of superficial skin lesions.”
§ Aminolevulinic Acid (ALA) as a Prodrug in Photodynamic Therapy of Cancer > 7. Clinical Indications for ALA and Its Esters
“MAL was approved in the treatment of actinic keratosis and nonmelanoma skin cancers (basal cell carcinoma) in Australia, New Zealand and some European countries. MAL, administered in a form of a cream, 3 hours after application under occlusion is activated with red light usually in a total dose of 75 J/cm2.”
Citations
Cites
Dougherty, T. J., Gomer, C. J., Henderson, B. W., Jori, G., Kessel, D., Korbelik, M., Moan, J., & Peng, Q. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.12.889 · Cited by 4,716
Gomer, C. J. (1988) · Cited by 4,174
Heme oxygenase: Function, multiplicity, regulatory mechanisms, and clinical applications
Maines, M. D. (1988) · The FASEB Journal · doi:10.1096/fasebj.2.10.3290025 · Cited by 1,707
Photodynamic therapy with endogenous protoporphyrin
Kennedy, J. C., Pottier, R. H., & Pross, D. C. (1990) · Journal of Photochemistry and Photobiology B: Biology · doi:10.1016/1011-1344(90)85083-9 · Cited by 1,509
O’Connor, A. E., Gallagher, W. M., & Byrne, A. T. (2009) · Photochemistry and Photobiology · doi:10.1111/j.1751-1097.2009.00585.x · Cited by 1,191
Kennedy (1992) · doi:10.1016/1011-1344(92)85108-7 · Cited by 1,166
5-Aminolevulinic Acid-Based Photodynamic Therapy: Principles and Experimental Research
Peng, Q., Berg, K., Moan, J., Kongshaug, M., & Nesland, J. M. (1997) · Photochemistry and Photobiology · doi:10.1111/j.1751-1097.1997.tb08549.x · Cited by 615
Structure and Biodistribution Relationships of Photodynamic Sensitizers*
Boyle, R. W., & Dolphin, D. (1996) · Photochemistry and Photobiology · doi:10.1111/j.1751-1097.1996.tb03093.x · Cited by 498
Biosynthesis of heme in mammals
Ajioka, R. S., Phillips, J. D., & Kushner, J. P. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2006.05.005 · Cited by 493
Oxygen Consumption and Diffusion Effects in Photodynamic Therapy
Foster, T. H., Murant, R. S., Bryant, R. G., Knox, R. S., Gibson, S. L., & Hilf, R. (1991) · Radiation Research · doi:10.2307/3577919 · Cited by 400
Cited by
BODIPY dyes in photodynamic therapy
Kamkaew, A., Lim, S. H., Lee, H. B., Kiew, L. V., Chung, L. Y., & Burgess, K. (2013) · Chem. Soc. Rev. · doi:10.1039/c2cs35216h · Cited by 2,104
Wu, G., Zhang, J., Zhao, Q., Zhuang, W., Ding, J., Zhang, C., Gao, H., Pang, D., Pu, K., & Xie, H. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.201913700 · Cited by 269
Photodynamic Therapy: A Compendium of Latest Reviews
Algorri, J. F., Ochoa, M., Roldán-Varona, P., Rodríguez-Cobo, L., & López-Higuera, J. M. (2021) · Cancers · doi:10.3390/cancers13174447 · Cited by 263
Dias, L. D., Blanco, K. C., Mfouo-Tynga, I. S., Inada, N. M., & Bagnato, V. S. (2020) · Journal of Photochemistry and Photobiology C: Photochemistry Reviews · doi:10.1016/j.jphotochemrev.2020.100384 · Cited by 251
Extracellular Metabolites from Industrial Microalgae and Their Biotechnological Potential
Liu, L., Pohnert, G., & Wei, D. (2016) · Marine Drugs · doi:10.3390/md14100191 · Cited by 193
“5-Aminolevulinic acid (ALA), which is a precursor of tetrapyrroles such as chlorophyll, haem, and vitamin B12, is used as a degradable insecticide and growth-promoting factor for plants [97].”
Background
Metadata
- Authors
- Wachowska, M., Muchowicz, A., Firczuk, M., Gabrysiak, M., Winiarska, M., Wańczyk, M., Bojarczuk, K., & Golab, J.
- Affiliations
- Medical University of Warsaw (PL)
- Department of Immunology, Centre of Biostructure Research, Medical University of Warsaw, Banacha 1A F Building, 02-097 Warsaw, Poland
- ORCID
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2011-05-19
- Volume
- 16
- Issue
- 5
- Pages
- 4140-4164
- ISSN
- 1420-3049 (ISSN-L)
- PMC
- PMC6263343
- OpenAlex
- W1976436613
- Semantic Scholar
- 4c745297bf1ff574274bed2dbd865f2a7d5cc6ee
- Cited by
- 265
- References
- 161
- Citations by year
- 2026: 5 · 2025: 14 · 2024: 28 · 2023: 19 · 2022: 14 · 2021: 24 · 2020: 36 · 2019: 23 · 2018: 17 · 2017: 24 · 2016: 25 · 2015: 10 · 2014: 13 · 2013: 4 · 2012: 9
- FWCI
- 7.03
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Molecules (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Fundacja na rzecz Nauki Polskiej
- Servier
- European Regional Development Fund (POIG. 01.01.02-00-008/08)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Photodynamic Therapy Research Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Porphyrin Metabolism and Disorders
- Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
- Keywords
- 5-aminolevulinic acid, photodynamic therapy, prodrugs, protoporphyrin IX, photosensitizers, ferrochelatase, heme biosynthesis, cancer therapy, heme oxygenase
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Aminolevulinic Acid (ALA) as a Prodrug in Photodynamic Therapy of Cancer. https://app.cochat.ai/papers/10.3390/molecules16054140
- The paper
- Wachowska, M., Muchowicz, A., Firczuk, M., Gabrysiak, M., Winiarska, M., Wańczyk, M., Bojarczuk, K., & Golab, J. (2011). Aminolevulinic Acid (ALA) as a Prodrug in Photodynamic Therapy of Cancer. Molecules. https://doi.org/10.3390/molecules16054140
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.